Home
About Us
Pipeline
Investors
News & Events
Careers
| S*BIO Vision | Background | S*BIO Management | Board of Directors | Scientific Advisory Board | Corporate Values |
| Clinical Trials | R&D Programmes | Technologies & Capabilities | S*BIO’s Functional Capabilities | Publications |
| Investors | Partnerships |
| News & Press Releases | Participation in Events |
| Join Our Team | Job Openings | How to Apply |
 |
 |
|
Every great advance in science has issued from a new audacity of imagination. John Dewey |
|
|
|
Partnerships The formation of strategic partnerships with leading pharmaceutical and biotechnology companies is a key element of S*BIO business strategy and is crucial in building long term value and success for S*BIO. With a solid pipeline and established expertise and capabilities in oncology, S*BIO is well positioned to be the partner and collaborator of choice in the development of breakthrough cancer therapies. S*BIO welcomes oncology partnerships/strategic alliances to complement and/or accelerate our internal discovery efforts, leverage on the expertise of our partners and to maximise the value and potential of our pipeline and platform:  Co-development/out-licensing of S*BIO’s lead HDAC inhibitor in oncology indications In-licensing of lead optimization/preclinical/early clinical small molecule product candidates for oncology indications Research collaborations or out-licensing of S*BIO’s proprietary compounds for non-oncology indicationsWe welcome and appreciate your interest in S*BIO, and look forward to discussing business development opportunities. For more information, contact us at invest@sbio.com
|